1. SCM "Povernei", 2. Inst. Endocrinology "Parhon", Bucharest -Romania Aim. Re-Analyzing the effect on prostatic volume of injectable testosterone undecanoat depot (TUD) in hypogonadic patients without prostatic cancer. Material&Method. A. Patients at onset 173 men with hypogonadism (median age: 64 y). B. Distribution: by decade. C. 1000 mg TUD (Nebido R -Bayer-Schering Pharma) was administrated at 3 months i.m. D. Prostate volume (PV) appreciated by per-abdominal ultrasound: 3,5 MHz probe, elliptical volume (cm3), Aloka 550. E. Time of analysis: before starting testosterone (T0), after ½ (T1), 3 (T2), 6 months (T3), 1 (T4), 2 (T5), 3 years (T6), 4 (T7), 5 (T8), and 6 years (T9). F. Maximum increment from P0 was noted  %. Average increment was noted  A %. G. Statistical analysis by Student test (p). Results. I. All average data of prostatic volume are tabulated.
Conclusions
Maximum increment ( M %) per decade, including the moment ( M % at) and average increment ( A %). II. PV at T0 increases with age, from 17,33 (19-29y) to 47,41 (80-89y), p=0,0007. III. Considering all observations (some at 5/6 years), TUD did not increase PV significantly (average of increment = 5,51). IV. Inside a specific decade no significant increased in PV was registered: all p >0,05 (80-89 decade p = 0,057). V. In some patients, especially from 50-79 years, TUD could decrease slightly prostatic volume.
Considering the risk for prostate (in elderly), testosterone undecanoat 1000 mg depot injectable is a safe treatment, even after 3 to 6 years of administration. Precautions should be accorded to men over 80 y old, after the third administration. Further observation needed. 
